Rocket Pharmaceuticals is trading 6.29% up at $3.58 after broad biotechnology sentiment strengthened on positive mRNA cancer-vaccine trial results.
- No fresh company-specific announcement was identified for August 19, 2026.
- Recent disclosures include second-quarter results published August 10 and positive RP-A501 safety data announced August 3; neither directly explains today’s move.
- The sector catalyst is the clearest explanation, with broader market rotation providing additional support.